Mallinckrodt PLC Stock Price, News & Analysis (NYSE:MNK)

$22.38 -0.07 (-0.31 %)
(As of 11/17/2017 05:27 AM ET)
Previous Close$22.45
Today's Range$21.91 - $22.58
52-Week Range$19.00 - $58.09
Volume2.57 million shs
Average Volume2.52 million shs
Market Capitalization$2.13 billion
P/E Ratio2.93
Dividend YieldN/A
Beta1.46

About Mallinckrodt PLC (NYSE:MNK)

Mallinckrodt PLC logoMallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.


Industry, Sector and Symbol:
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Specialty & Advanced Pharmaceuticals
  • Symbol: NYSE:MNK
  • CUSIP: N/A
  • Web: mallinckrodt.com
Debt:
  • Debt-to-Equity Ratio: 1.08%
  • Current Ratio: 1.38%
  • Quick Ratio: 1.05%
Price-To-Earnings:
  • Trailing P/E Ratio: 2.93
  • Forward P/E Ratio: 3.10
  • P/E Growth: 0.32
Sales & Book Value:
  • Annual Sales: $829.9 million
  • Price / Sales: 2.56
  • Cash Flow: $0.26 per share
  • Price / Cash: 86.20
  • Book Value: $53.82 per share
  • Price / Book: 0.42
Profitability:
  • Trailing EPS: ($0.02)
  • Net Income: ($153,200,000.00)
  • Net Margins: 11.43%
  • Return on Equity: 14.79%
  • Return on Assets: 5.07%
Misc:
  • Employees: 4,500
  • Outstanding Shares: 95,000,000
 

Frequently Asked Questions for Mallinckrodt PLC (NYSE:MNK)

What is Mallinckrodt PLC's stock symbol?

Mallinckrodt PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt PLC's stock buyback program work?

Mallinckrodt PLC announced that its Board of Directors has authorized a stock buyback plan on Sunday, April 9th 2017, which permits the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy up to 18.5% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's management believes its stock is undervalued.

How were Mallinckrodt PLC's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) posted its quarterly earnings results on Tuesday, November, 7th. The company reported $1.97 EPS for the quarter, beating analysts' consensus estimates of $1.80 by $0.17. The business had revenue of $793.90 million for the quarter, compared to analysts' expectations of $808.93 million. Mallinckrodt PLC had a return on equity of 14.79% and a net margin of 11.43%. Mallinckrodt PLC's revenue was down 10.5% on a year-over-year basis. During the same period in the prior year, the business posted $2.04 earnings per share. View Mallinckrodt PLC's Earnings History.

When will Mallinckrodt PLC make its next earnings announcement?

Mallinckrodt PLC is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Mallinckrodt PLC.

Where is Mallinckrodt PLC's stock going? Where will Mallinckrodt PLC's stock price be in 2017?

18 brokerages have issued 1-year price objectives for Mallinckrodt PLC's stock. Their predictions range from $23.00 to $98.00. On average, they expect Mallinckrodt PLC's share price to reach $49.31 in the next year. View Analyst Ratings for Mallinckrodt PLC.

What are Wall Street analysts saying about Mallinckrodt PLC stock?

Here are some recent quotes from research analysts about Mallinckrodt PLC stock:

  • 1. According to Zacks Investment Research, "Mallinckrodt is focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures to transform the portfolio. The company sold its Nuclear Imaging business and Intrathecal Therapy business. Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments and we expect Acthar sales to drive growth. However, sales of Therakos is expected to decline. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. The company expects double-digit declines in revenues from this segment. Shares of the company have underperformed the industry so far in 2017. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax." (11/6/2017)
  • 2. Mizuho analysts commented, "We reiterate our Buy rating and $73 PT and push back against short-seller inaccuracies and Acthar pricing concerns." (5/31/2017)
  • 3. Guggenheim analysts commented, "Although any potential competition for MNK's largest single drug, Acthar, is a concern, we think that it will take at least several years for Marathon to even establish proof of concept for its product, which means there is no near-to-mid-term threat here. We forecast Acthar sales of $1.2B in '16 and total MNK sales of $3.3B. We believe that MNK's execution of its stated business objectives is underappreciated and would note that the company has a demonstrated record of success, supported by consistent earnings beats over the last five quarters. We continue to believe strong execution of MNK's growth initiatives will drive P/E multiple expansion (from 6x to at least 10x, average pharma trough multiple) and put MNK shares back on a path to $70+." (1/19/2017)

Who are some of Mallinckrodt PLC's key competitors?

Who are Mallinckrodt PLC's key executives?

Mallinckrodt PLC's management team includes the folowing people:

  • Melvin D. Booth Ph.D. CPA, Independent Chairman of the Board (Age 71)
  • Mark C. Trudeau, President, Chief Executive Officer, Director (Age 55)
  • Matthew K. Harbaugh, Chief Financial Officer, Executive Vice President (Age 46)
  • Ian J. Watkins, Chief Human Resource Officer (Age 54)
  • Ronald K. Lloyd, Executive Vice President and President - Hospital Therapies (Age 56)
  • Gary M. Phillips M.D., Executive Vice President and Chief Strategy Officer (Age 51)
  • Steven Romano, Executive Vice President and Chief Scientific Officer (Age 57)
  • Frank Scholz, Executive Vice President of Global Operations and President - Specialty Generics (Age 47)
  • Hugh O'Neill, Senior Vice President and President - Autoimmune and Rare Diseases (Age 53)
  • Raymond J. Furey, Chief Compliance Officer (Age 48)

Who owns Mallinckrodt PLC stock?

Mallinckrodt PLC's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (2.66%), Ameriprise Financial Inc. (2.00%), Alyeska Investment Group L.P. (1.62%), Orbimed Advisors LLC (1.55%), Prudential Financial Inc. (1.39%) and Bank of New York Mellon Corp (1.18%). Company insiders that own Mallinckrodt PLC stock include Coleman N Lannum III, David R Carlucci, Gary M Phillips, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Institutional Ownership Trends for Mallinckrodt PLC.

Who sold Mallinckrodt PLC stock? Who is selling Mallinckrodt PLC stock?

Mallinckrodt PLC's stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., SG Americas Securities LLC, Teacher Retirement System of Texas, Meyer Handelman Co., APG Asset Management N.V., AMP Capital Investors Ltd, PGGM Investments and Rhumbline Advisers. View Insider Buying and Selling for Mallinckrodt PLC.

Who bought Mallinckrodt PLC stock? Who is buying Mallinckrodt PLC stock?

Mallinckrodt PLC's stock was purchased by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Alyeska Investment Group L.P., Bank of New York Mellon Corp, Dimensional Fund Advisors LP, First Manhattan Co., Broadwood Capital Inc., Principal Financial Group Inc. and Orbimed Advisors LLC. Company insiders that have bought Mallinckrodt PLC stock in the last two years include Coleman N Lannum III, David R Carlucci, Gary M Phillips, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Insider Buying and Selling for Mallinckrodt PLC.

How do I buy Mallinckrodt PLC stock?

Shares of Mallinckrodt PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mallinckrodt PLC's stock price today?

One share of Mallinckrodt PLC stock can currently be purchased for approximately $22.38.

How big of a company is Mallinckrodt PLC?

Mallinckrodt PLC has a market capitalization of $2.13 billion and generates $829.9 million in revenue each year. The company earns ($153,200,000.00) in net income (profit) each year or ($0.02) on an earnings per share basis. Mallinckrodt PLC employs 4,500 workers across the globe.

How can I contact Mallinckrodt PLC?

Mallinckrodt PLC's mailing address is 3 Lotus Park, The Causeway, STAINES, TW18 3AG, United Kingdom. The company can be reached via phone at +44-1784-636700 or via email at [email protected]


MarketBeat Community Rating for Mallinckrodt PLC (NYSE MNK)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  582 (Vote Outperform)
Underperform Votes:  318 (Vote Underperform)
Total Votes:  900
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Mallinckrodt PLC (NYSE:MNK)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 9 Hold Ratings, 9 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $49.31 (120.31% upside)

Consensus Price Target History for Mallinckrodt PLC (NYSE:MNK)

Price Target History for Mallinckrodt PLC (NYSE:MNK)

Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017Canaccord GenuitySet Price TargetHold$24.00N/AView Rating Details
11/8/2017Stifel NicolausLower Price TargetBuy$70.00 -> $50.00N/AView Rating Details
11/8/2017Morgan StanleyLower Price TargetEqual Weight$40.00 -> $27.00N/AView Rating Details
11/8/2017BMO Capital MarketsLower Price TargetOutperform$38.00N/AView Rating Details
11/8/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$55.00N/AView Rating Details
11/8/2017Jefferies Group LLCInitiated CoverageMarket Perform -> Buy$60.00 -> $30.00N/AView Rating Details
11/8/2017Barclays PLCDowngradeOverweight -> Equal Weight$65.00 -> $23.00N/AView Rating Details
11/8/2017Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
11/7/2017Citigroup Inc.DowngradeBuy -> Hold$44.00 -> $28.00N/AView Rating Details
11/7/2017Deutsche Bank AGDowngradeBuy -> Hold$44.00 -> $28.00N/AView Rating Details
11/2/2017Cantor FitzgeraldReiterated RatingBuy$52.00N/AView Rating Details
10/21/2017Piper Jaffray CompaniesSet Price TargetBuy$67.00N/AView Rating Details
10/15/2017MizuhoReiterated RatingHold$40.00N/AView Rating Details
9/19/2017Oppenheimer Holdings, Inc.Lower Price Target$70.00 -> $48.00LowView Rating Details
8/9/2017Raymond James Financial, Inc.Lower Price TargetOutperform$65.00 -> $58.00LowView Rating Details
4/1/2017GuggenheimSet Price TargetBuy$98.00LowView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformLowView Rating Details
1/25/2017J P Morgan Chase & CoSet Price TargetHold$78.00N/AView Rating Details
3/16/2016Northland SecuritiesReiterated RatingBuy$95.00N/AView Rating Details
2/2/2016NomuraReiterated RatingNeutral$100.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Mallinckrodt PLC (NYSE:MNK)

Earnings by Quarter for Mallinckrodt PLC (NYSE:MNK)

Earnings History by Quarter for Mallinckrodt PLC (NYSE MNK)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018$1.97N/AView Earnings Details
11/7/2017Q3 2017$1.80$1.97$808.93 million$793.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017$1.73$1.85$829.56 million$824.50 millionViewListenView Earnings Details
5/8/2017Q1 2017$1.63$1.68$781.23 million$810.90 millionViewListenView Earnings Details
2/7/2017Q117$1.82$1.91$827.12 million$829.90 millionViewListenView Earnings Details
11/29/2016Q416$1.98$2.04$880.10 million$887.20 millionViewListenView Earnings Details
8/2/2016Q316$2.01$2.20$920.35 million$970.60 millionViewListenView Earnings Details
5/3/2016Q216$1.72$2.01$878.70 million$918.00 millionViewListenView Earnings Details
2/2/2016Q116$1.78$2.09$888.33 million$915.00 millionViewListenView Earnings Details
11/23/2015Q415$1.77$1.84$869.41 million$882.40 millionViewListenView Earnings Details
8/4/2015Q315$1.82$2.05$983.81 million$965.10 millionViewListenView Earnings Details
5/5/2015Q215$1.48$1.72$860.89 million$909.90 millionViewListenView Earnings Details
2/3/2015Q115$1.57$1.84$880.12 million$866.00 millionViewListenView Earnings Details
11/19/2014Q414$1.41$1.68$759.04 million$789.00 millionViewListenView Earnings Details
8/7/2014Q314$0.86$1.20$278.80 million$653.10 millionViewListenView Earnings Details
5/8/2014Q214$0.79$0.95$566.50 million$557.80 millionViewListenView Earnings Details
2/6/2014Q1$0.66$0.88$539.24 million$540.20 millionViewListenView Earnings Details
11/7/2013$0.85$1.02$572.57 million$552.20 millionViewListenView Earnings Details
8/9/2013Q3 2013$0.78$0.49$557.22 million$570.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)
2017 EPS Consensus Estimate: $7.28
2018 EPS Consensus Estimate: $7.88
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.54$1.84$1.71
Q2 20173$1.70$1.95$1.80
Q3 20173$1.81$1.89$1.86
Q4 20173$1.75$2.02$1.91
Q1 20183$1.55$1.82$1.66
Q2 20182$1.66$2.15$1.91
Q3 20182$2.07$2.10$2.09
Q4 20182$1.98$2.48$2.23
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Mallinckrodt PLC (NYSE MNK)

Insider Ownership Percentage: 0.77%
Institutional Ownership Percentage: 98.83%
Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)
Institutional Ownership by Quarter for Mallinckrodt PLC (NYSE:MNK)

Insider Trades by Quarter for Mallinckrodt PLC (NYSE MNK)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2017Joann A ReedDirectorBuy1,000$21.50$21,500.00View SEC Filing  
11/13/2017Steven J. RomanoVPBuy2,000$21.96$43,920.00View SEC Filing  
11/10/2017Mark TrudeauCEOBuy5,000$22.28$111,400.00View SEC Filing  
11/9/2017David R CarlucciDirectorBuy10,000$21.83$218,300.00View SEC Filing  
11/9/2017Michael-Bryant HicksGeneral CounselBuy7,900$20.80$164,320.00View SEC Filing  
8/30/2017Meredith B. FischerInsiderBuy1,280$39.63$50,726.40View SEC Filing  
6/9/2017Steven J. RomanoVPBuy1,000$39.88$39,880.00View SEC Filing  
6/8/2017Hugh M. O'neillVPBuy1,000$40.24$40,240.00View SEC Filing  
6/5/2017Coleman N Lannum IIIVPBuy500$39.33$19,665.00View SEC Filing  
6/2/2017Coleman N Lannum IIIVPBuy1,350$42.89$57,901.50View SEC Filing  
5/12/2017Coleman N. Lannum IIIVPBuy1,968$46.20$90,921.60View SEC Filing  
3/10/2017Matthew K. HarbaughCFOBuy600$49.19$29,514.00View SEC Filing  
3/7/2017Michael-Bryant HicksGeneral CounselBuy290$50.35$14,601.50View SEC Filing  
2/23/2017Meredith B. FischerInsiderBuy2,000$54.34$108,680.00View SEC Filing  
2/14/2017Mark TrudeauInsiderBuy1,000$50.47$50,470.00View SEC Filing  
2/10/2017Steven J. RomanoVPBuy1,000$49.68$49,680.00View SEC Filing  
5/10/2016Hugh M O'neillVPBuy1,653$60.99$100,816.47View SEC Filing  
5/10/2016Matthew K HarbaughCFOBuy500$59.37$29,685.00View SEC Filing  
5/6/2016Mark TrudeauCEOBuy1,000$56.02$56,020.00View SEC Filing  
5/6/2016Steven J RomanoVPBuy900$56.00$50,400.00View SEC Filing  
3/4/2016Coleman N Lannum IIIVPBuy2,600$62.63$162,838.00View SEC Filing  
2/26/2016Meredith B FischerVPBuy1,400$69.80$97,720.00View SEC Filing  
2/12/2016Coleman N Lannum IIIVPBuy600$59.66$35,796.00View SEC Filing  
2/10/2016Coleman N Lannum IIIVPBuy1,300$62.58$81,354.00View SEC Filing  
2/9/2016Matthew K. HarbaughCFOBuy1,300$63.00$81,900.00View SEC Filing  
2/8/2016Coleman N. Lannum IIIVPBuy800$66.37$53,096.00View SEC Filing  
12/22/2015Coleman N Lannum IIISVPBuy500$72.50$36,250.00View SEC Filing  
12/11/2015Terrance L CarlsonGeneral CounselBuy1,000$69.10$69,100.00View SEC Filing  
12/2/2015Gary M. PhillipsVPBuy1,000$72.17$72,170.00View SEC Filing  
11/30/2015Mark TrudeauCEOBuy1,350$65.89$88,951.50View SEC Filing  
11/27/2015Coleman N Lannum IIISVPBuy1,200$66.86$80,232.00View SEC Filing  
11/27/2015Meredith B FischerVPBuy2,200$66.93$147,246.00View SEC Filing  
11/27/2015Terrance L CarlsonGeneral CounselBuy1,000$66.54$66,540.00View SEC Filing  
8/25/2015Hugh M O'neillSVPBuy1,197$83.52$99,973.44View SEC Filing  
8/25/2015Mark TrudeauCEOBuy1,000$83.08$83,080.00View SEC Filing  
8/21/2015Coleman N Lannum IIISVPBuy2,375$88.52$210,235.00View SEC Filing  
8/21/2015Mark TrudeauCEOBuy2,000$88.45$176,900.00View SEC Filing  
6/4/2015Coleman N Lannum IIIVPBuy1,300$126.41$164,333.00View SEC Filing  
6/2/2015Matthew K HarbaughCFOSell22,106$128.64$2,843,715.84View SEC Filing  
5/18/2015Mario D SaltarelliVPSell4,580$127.44$583,675.20View SEC Filing  
5/13/2015Don M BaileyDirectorSell51,417$122.45$6,296,011.65View SEC Filing  
5/11/2015Sandra L HattenVPSell2,024$122.29$247,514.96View SEC Filing  
4/13/2015Don M BaileyDirectorSell40,000$127.61$5,104,400.00View SEC Filing  
3/13/2015Don M BaileyDirectorSell40,000$123.40$4,936,000.00View SEC Filing  
2/13/2015Don M BaileyDirectorSell33,891$114.63$3,884,925.33View SEC Filing  
2/2/2015Mark TrudeauCEOSell11,925$105.94$1,263,334.50View SEC Filing  
1/9/2015Mark TrudeauCEOSell15,720$102.00$1,603,440.00View SEC Filing  
12/22/2014Peter G EdwardsVPSell1,265$99.69$126,107.85View SEC Filing  
12/18/2014Mark TrudeauCEOSell13,831$93.59$1,294,443.29View SEC Filing  
9/10/2014Raymond J FureyVPSell5,441$85.90$467,381.90View SEC Filing  
9/8/2014Don M BaileyDirectorSell221,177$85.23$18,850,915.71View SEC Filing  
9/5/2014Raymond J FureyVPSell15,000$85.47$1,282,050.00View SEC Filing  
9/5/2014Virgil D ThompsonDirectorSell25,000$83.76$2,094,000.00View SEC Filing  
9/2/2014Raymond J FureyVPSell10,303$81.61$840,827.83View SEC Filing  
8/29/2014Raymond J FureyVPSell4,840$80.90$391,556.00View SEC Filing  
8/19/2014Joseph A ZaccagninoDirectorBuy3,000$71.06$213,180.00View SEC Filing  
8/13/2014Paulson & Co IncMajor ShareholderBuy132,100$69.80$9,220,580.00View SEC Filing  
8/12/2014J Martin CarrollDirectorBuy2,000$69.24$138,480.00View SEC Filing  
8/12/2014Paulson & Co IncMajor ShareholderBuy467,900$68.78$32,182,162.00View SEC Filing  
8/11/2014Paulson & Co IncMajor ShareholderBuy207,900$69.70$14,490,630.00View SEC Filing  
8/7/2014Paulson & Co IncMajor ShareholderBuy700,200$70.15$49,119,030.00View SEC Filing  
8/1/2014Paulson & Co IncMajor ShareholderBuy275,000$69.60$19,140,000.00View SEC Filing  
6/11/2014Melvin D BoothDirectorBuy4,000$76.05$304,200.00View SEC Filing  
5/9/2014Paulson & Co Incmajor shareholderBuy786,207$73.63$57,888,421.41View SEC Filing  
2/3/2014Mark TrudeauCEOSell14,890$56.12$835,626.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Mallinckrodt PLC (NYSE:MNK)

Latest Headlines for Mallinckrodt PLC (NYSE MNK)

Source:
DateHeadline
Mallinckrodt (MNK) Presents Health Economic Data on OFIRMEV Injection at ASRA MeetingMallinckrodt (MNK) Presents Health Economic Data on OFIRMEV Injection at ASRA Meeting
www.streetinsider.com - November 18 at 12:46 AM
Mallinckrodt To Present At The BMO Prescriptions for Success Healthcare ConferenceMallinckrodt To Present At The BMO Prescriptions for Success Healthcare Conference
finance.yahoo.com - November 15 at 6:26 AM
Why Mallinckrodt Cratered - Mallinckrodt PLC (NYSE:MNK ... - Seeking AlphaWhy Mallinckrodt Cratered - Mallinckrodt PLC (NYSE:MNK ... - Seeking Alpha
seekingalpha.com - November 14 at 2:59 AM
Mallinckrodt Stock Lowered to Neutral at UBS Over Persisting ConcernsMallinckrodt Stock Lowered to 'Neutral' at UBS Over Persisting Concerns
finance.yahoo.com - November 14 at 2:59 AM
Mallinckrodt Bull Turns Bear, Slashes Price Target By 66%Mallinckrodt Bull Turns Bear, Slashes Price Target By 66%
finance.yahoo.com - November 14 at 2:59 AM
Insider Buying: Mallinckrodt PLC (MNK) Director Acquires 1,000 Shares of StockInsider Buying: Mallinckrodt PLC (MNK) Director Acquires 1,000 Shares of Stock
www.americanbankingnews.com - November 13 at 7:52 PM
Mallinckrodt PLC (MNK) VP Purchases $43,920.00 in StockMallinckrodt PLC (MNK) VP Purchases $43,920.00 in Stock
www.americanbankingnews.com - November 13 at 6:54 PM
Mallinckrodt PLC (MNK) CEO Buys $111,400.00 in StockMallinckrodt PLC (MNK) CEO Buys $111,400.00 in Stock
www.americanbankingnews.com - November 13 at 6:26 PM
David R. Carlucci Acquires 10,000 Shares of Mallinckrodt PLC (MNK) StockDavid R. Carlucci Acquires 10,000 Shares of Mallinckrodt PLC (MNK) Stock
www.americanbankingnews.com - November 13 at 4:51 PM
Mallinckrodt PLC (MNK) General Counsel Michael-Bryant Hicks Purchases 7,900 SharesMallinckrodt PLC (MNK) General Counsel Michael-Bryant Hicks Purchases 7,900 Shares
www.americanbankingnews.com - November 13 at 4:50 PM
FY2017 EPS Estimates for Mallinckrodt PLC Decreased by Cantor Fitzgerald (MNK)FY2017 EPS Estimates for Mallinckrodt PLC Decreased by Cantor Fitzgerald (MNK)
www.americanbankingnews.com - November 13 at 2:58 AM
Mallinckrodt Plc: Strong price momentum but will it sustain?Mallinckrodt Plc: Strong price momentum but will it sustain?
finance.yahoo.com - November 12 at 7:43 AM
Stock Traders Purchase High Volume of Call Options on Mallinckrodt PLC (MNK)Stock Traders Purchase High Volume of Call Options on Mallinckrodt PLC (MNK)
www.americanbankingnews.com - November 11 at 2:42 AM
Jefferies Group Analysts Decrease Earnings Estimates for Mallinckrodt PLC (MNK)Jefferies Group Analysts Decrease Earnings Estimates for Mallinckrodt PLC (MNK)
www.americanbankingnews.com - November 10 at 3:04 PM
FY2017 Earnings Forecast for Mallinckrodt PLC Issued By Jefferies Group (MNK)FY2017 Earnings Forecast for Mallinckrodt PLC Issued By Jefferies Group (MNK)
www.americanbankingnews.com - November 9 at 7:35 AM
Mallinckrodt plc (MNK) PT Lowered to $30 at JefferiesMallinckrodt plc (MNK) PT Lowered to $30 at Jefferies
www.streetinsider.com - November 9 at 1:50 AM
Mallinckrodt plc (MNK) PT Lowered to $24 at Canaccord Genuity - StreetInsider.comMallinckrodt plc (MNK) PT Lowered to $24 at Canaccord Genuity - StreetInsider.com
www.streetinsider.com - November 8 at 8:48 PM
Goldman Sachs Downgrades Mallinckrodt plc (MNK) to Neutral - StreetInsider.comGoldman Sachs Downgrades Mallinckrodt plc (MNK) to Neutral - StreetInsider.com
www.streetinsider.com - November 8 at 8:48 PM
ETFs with exposure to Mallinckrodt Plc : November 8, 2017ETFs with exposure to Mallinckrodt Plc : November 8, 2017
finance.yahoo.com - November 8 at 8:48 PM
Mallinckrodt Enters Oversold Territory (MNK) - NasdaqMallinckrodt Enters Oversold Territory (MNK) - Nasdaq
www.nasdaq.com - November 8 at 3:48 PM
Mallinckrodt plc (MNK) PT Lowered to $40 at Piper Jaffray - StreetInsider.comMallinckrodt plc (MNK) PT Lowered to $40 at Piper Jaffray - StreetInsider.com
www.streetinsider.com - November 8 at 3:48 PM
Wells Fargo Downgrades Mallinckrodt plc (MNK) to Market Perform - StreetInsider.comWells Fargo Downgrades Mallinckrodt plc (MNK) to Market Perform - StreetInsider.com
www.streetinsider.com - November 8 at 3:48 PM
Mallinckrodt shares drop 8.6% after Q3 profit, revenue missesMallinckrodt shares drop 8.6% after Q3 profit, revenue misses
finance.yahoo.com - November 8 at 3:48 PM
Pharma company Mallinckrodt on pace for worst day ever, s...Pharma company Mallinckrodt on pace for worst day ever, s...
finance.yahoo.com - November 8 at 3:48 PM
Edited Transcript of MNK earnings conference call or presentation 7-Nov-17 1:30pm GMTEdited Transcript of MNK earnings conference call or presentation 7-Nov-17 1:30pm GMT
finance.yahoo.com - November 8 at 3:47 PM
Charting the Market: Mallinckrodt Tumbles 35%Charting the Market: Mallinckrodt Tumbles 35%
finance.yahoo.com - November 8 at 3:47 PM
Mallinckrodt Nosedives After Sales Lag, Though Earnings Top ViewsMallinckrodt Nosedives After Sales Lag, Though Earnings Top Views
finance.yahoo.com - November 8 at 3:47 PM
[$$] Why Mallinckrodt’s Woes Matter to All Drug Makers[$$] Why Mallinckrodt’s Woes Matter to All Drug Makers
finance.yahoo.com - November 8 at 3:47 PM
Mallinckrodt shares drop after Goldman downgradeMallinckrodt shares drop after Goldman downgrade
finance.yahoo.com - November 8 at 3:47 PM
Company News For Nov 8, 2017Company News For Nov 8, 2017
finance.yahoo.com - November 8 at 3:47 PM
Heres Why Mallinckrodt Stock Plummeted to an All-Time LowHere's Why Mallinckrodt Stock Plummeted to an All-Time Low
finance.yahoo.com - November 8 at 3:47 PM
Mallinckrodt: Look Out Below!Mallinckrodt: Look Out Below!
finance.yahoo.com - November 8 at 3:47 PM
Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3
finance.yahoo.com - November 8 at 3:47 PM
Mallinckrodt PLC (MNK) Downgraded by Deutsche Bank AG to "Hold"Mallinckrodt PLC (MNK) Downgraded by Deutsche Bank AG to "Hold"
www.americanbankingnews.com - November 7 at 9:06 PM
Mallinckrodt PLC (MNK) Lowered to Hold at Citigroup Inc.Mallinckrodt PLC (MNK) Lowered to Hold at Citigroup Inc.
www.americanbankingnews.com - November 7 at 4:36 PM
Mallinckrodt PLC (MNK) Issues Quarterly  Earnings ResultsMallinckrodt PLC (MNK) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 7 at 2:40 PM
Mallinckrodt plc Reports Earnings Results for Third Quarter of Fiscal 2017 - PR Newswire (press release)Mallinckrodt plc Reports Earnings Results for Third Quarter of Fiscal 2017 - PR Newswire (press release)
www.prnewswire.com - November 7 at 6:57 AM
Earnings Reaction History: Mallinckrodt plc, 45.5% Follow-Through Indicator, 5.8% Sensitive - NasdaqEarnings Reaction History: Mallinckrodt plc, 45.5% Follow-Through Indicator, 5.8% Sensitive - Nasdaq
www.nasdaq.com - November 7 at 6:57 AM
Mallinckrodt plc Reports Earnings Results for Third Quarter of Fiscal 2017Mallinckrodt plc Reports Earnings Results for Third Quarter of Fiscal 2017
finance.yahoo.com - November 7 at 6:57 AM
Mallinckrodt tops 3Q profit forecastsMallinckrodt tops 3Q profit forecasts
finance.yahoo.com - November 7 at 6:57 AM
Mallinckrodt Plc to Host Earnings CallMallinckrodt Plc to Host Earnings Call
finance.yahoo.com - November 7 at 6:57 AM
Mallinckrodt PLC (MNK) Given Average Recommendation of "Buy" by AnalystsMallinckrodt PLC (MNK) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 6 at 6:02 AM
Mallinckrodt will buy biotech Ocera Therapeutics for about $42 mln - MarketWatchMallinckrodt will buy biotech Ocera Therapeutics for about $42 mln - MarketWatch
www.marketwatch.com - November 4 at 5:25 AM
Mallinckrodt takes out Ocera Therapeutics for $42M in cash - Seeking AlphaMallinckrodt takes out Ocera Therapeutics for $42M in cash - Seeking Alpha
seekingalpha.com - November 4 at 5:25 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Ocera Therapeutics, Inc. - OCRXSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Ocera Therapeutics, Inc. - OCRX
finance.yahoo.com - November 4 at 5:25 AM
Zacks Investment Research Upgrades Mallinckrodt PLC (MNK) to HoldZacks Investment Research Upgrades Mallinckrodt PLC (MNK) to Hold
www.americanbankingnews.com - October 31 at 12:42 PM
Mallinckrodt PLC (MNK) to Release Earnings on TuesdayMallinckrodt PLC (MNK) to Release Earnings on Tuesday
www.americanbankingnews.com - October 31 at 11:34 AM
Mallinckrodt plc Presents Multiple Sclerosis (MS) Relapse Data at 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis2017)Mallinckrodt plc Presents Multiple Sclerosis (MS) Relapse Data at 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis2017)
finance.yahoo.com - October 27 at 8:03 AM
Patient Survey Studies Find Multiple Sclerosis Relapse is Underreported; Approximately Half of Patients Do Not Always Engage with Healthcare Practitioners During RelapsePatient Survey Studies Find Multiple Sclerosis Relapse is Underreported; Approximately Half of Patients Do Not Always Engage with Healthcare Practitioners During Relapse
finance.yahoo.com - October 27 at 8:03 AM
Mallinckrodt PLC (MNK) Upgraded to Hold by Zacks Investment ResearchMallinckrodt PLC (MNK) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - October 25 at 4:42 PM

Social Media

Financials

Chart

Mallinckrodt PLC (NYSE MNK) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.